Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still there's no justification for pps activity. Based on my research, this stock has been dormant for 10+ years? This is a shell company. Still watching and curious though.
Yes, since Sanofi got involved. Don't know what you think, but of all the public otc microcap out there, MYMX is the only one involved (past&present) with a big Pharma bec. of their technology platform. In my opinion only, MYMX is a strong M&A target.
This is my 2nd of only 3 posting allowed for a day. :(
GLTU
What 'ya think?
Check on MYMX.
CATALYSTS:
*** Collaborative project with Sanofi Pasteur(vaccine division of French Drugmaker Sanofi,NYSE:SNY) will come into conclusion before end of 2018.
*** Mymetics is leading a consortium of 4 european companies including giant CMO Catalent, NYSE:CTLT to develop a solid state thermostable cold chain independent vaccines (MACIVIVA)using Mymetics' HIV-1 vaccine since April 2015 and will come into conclusion before end of 2018.
The real deal is MYMX. A strong M&A target,imo. ***A sleeping gem*** Unbelievably UNDERVALUED! Check it out!
Looking great! Uptrend continues. :)
Yep! Got my initial position 3 weeks ago. Reaping gains!
You might want to keep an eye on MYMX as well!
GL
What do you think of this filings? TIA
ANTH President/CEO leaving - "Termination without Cause" ?
I'm assuming you sold out now?
Looks like you got your selling range for a short while.
GL
I'm out on the spike earlier. On watch for now!
GL
1M cheap shares? cool!
GLTY
My confidence is still high considering Dr. Christopher Henney as the Chairman of BOD. Pretty sure he led the recent acquisition of Cascadian Therapeutics (formerly Oncothyreon)of which also the chairman of bod, by Seattle Genetics. He is also a director at Cyclacel Pharmaceuticals (CYCC).
GL
We need a blockbuster news to go uptrend! Enough of this eroding pps.
Got it. Have a good day!
Nothing to do with BPMX. However, still depends on the discretion of mods to allow it or not as some other boards do.
ps sorry for the late response, I'm only allowed to post 3 a day and no pm feature.
Hi! will you be considerate reinstating my deleted post? TIA
Great! ANTH $$$
I hope you're right! My other holding mymx as well.
Definitely. Question is at what price?
When demands outweighs supply, the MMs will naked short. They will cover by forcing the pps downward when volume gets dry. Thereby causing panic, scaring the retail investors to sell.
Short Volume data for AXXA:
https://otcshortreport.com/#!/company/AXXA
Thanks for the heads up :)
April 23rd 2018 - The Best Stock Investment For 2018 - Mymetics Corp. (MYMX)
" Mymetics Corp (MYMX) and Sanofi are currently working on a redesigned study to compare the immunogenicity of Mymetics’ influenza virosomes with that of Sanofi Pasteur’s egg-based split vaccine."
https://askwarrenbuffet.blogspot.com/2018/02/the-best-investment-for-2018-is.html
Surprisingly, they didn't mention MACIVIVA!
Mymetics is leading a consortium of 4 other companies.
MACIVIVA = Game Changer = Disrupting the vaccine industry worldwide!
MACIVIVA latest Progress' Reporting Period Posted: https://cordis.europa.eu/result/rcn/194900_en.html
Copy of latest MACIVIVA presentation (downloadable): https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/
Would have been better in the hands of the Americans pps wise since 2012?
Dr. Christopher Henney, currently Chairman of BOD at Anthera Pharmaceuticals(ANTH) and Cascadian Therapeutics(CSCA)(formerly Oncothyreon)-recently acquired by Seattle Genetics, and Director at Cyclacel Therapeutics(CYCC); and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems like had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/
April 20th 2018 - The Best Stock Investment For 2018 - Mymetics Corp. (MYMX)
" Mymetics Corp (MYMX) and Sanofi are currently working on a redesigned study to compare the immunogenicity of Mymetics’ influenza virosomes with that of Sanofi Pasteur’s egg-based split vaccine."
https://askwarrenbuffet.blogspot.com/2018/02/the-best-investment-for-2018-is.html
Surprisingly, they didn't mention MACIVIVA!
Mymetics is leading a consortium of 4 other companies.
MACIVIVA = Game Changer = Disrupting the vaccine industry worldwide!
MACIVIVA latest Progress' Reporting Period Posted: https://cordis.europa.eu/result/rcn/194900_en.html
Copy of latest MACIVIVA presentation (downloadable): https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/
Would have been better in the hands of the Americans pps wise since 2012?
Dr. Christopher Henney, currently Director of Cyclacel Pharmaceuticals and chairman of BOD at Cascadian Therapeutics(CSCA)(formerly Oncothyreon)-recently acquired by Seattle Genetics, and Anthera Pharmaceuticals(ANTH); and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems like had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/
Less
April 20th 2018 - The Best Stock Investment For 2018 - Mymetics Corp. (MYMX)
" Mymetics Corp (MYMX) and Sanofi are currently working on a redesigned study to compare the immunogenicity of Mymetics’ influenza virosomes with that of Sanofi Pasteur’s egg-based split vaccine."
https://askwarrenbuffet.blogspot.com/2018/02/the-best-investment-for-2018-is.html
Surprisingly, they didn't mention MACIVIVA!
Mymetics is leading a consortium of 4 other companies.
MACIVIVA = Game Changer = Disrupting the vaccine industry worldwide!
MACIVIVA latest Progress' Reporting Period Posted: https://cordis.europa.eu/result/rcn/194900_en.html
Copy of latest MACIVIVA presentation (downloadable): https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/
Would have been better in the hands of the Americans pps wise since 2012?
Dr. Christopher Henney, currently Director of Cyclacel Pharmaceuticals and chairman of BOD at Cascadian Therapeutics(CSCA)(formerly Oncothyreon)-recently acquired by Seattle Genetics, and Anthera Pharmaceuticals(ANTH); and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems like had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/
Less
If events is looking good forward, why spend $5.3million to terminate a workplace's lease? Are they moving?
"The Company will, in accordance with the terms of the Lease, pay a termination fee to the Landlord of approximately $5.3 million on or before the Termination Date, which the Company believes is less than the potential total lease and operating expense cash obligations that could have been incurred over one year."
https://ih.advfn.com/p.php?pid=nmona&article=76440499
Seems the termination of lease is a good thing??? That's why NVAX is running hard north?
"the ability to terminate the Lease upon the occurrence of certain events."
https://ih.advfn.com/p.php?pid=nmona&article=76440499
What "occurence of certain events" could it be to trigger a termination of lease for a workplace??? Any thoughts? TIA
SEC Announces Enforcement Initiatives to Combat Cyber-Based Threats and Protect Retail Investors
FOR IMMEDIATE RELEASE
2017-176
Washington D.C., Sept. 25, 2017—
The Securities and Exchange Commission today announced two new initiatives that will build on its Enforcement Division’s ongoing efforts to address cyber-based threats and protect retail investors. The creation of a Cyber Unit that will focus on targeting cyber-related misconduct and the establishment of a retail strategy task force that will implement initiatives that directly affect retail investors reflect SEC Chairman Jay Clayton’s priorities in these important areas.
Cyber Unit
The Cyber Unit will focus the Enforcement Division’s substantial cyber-related expertise on targeting cyber-related misconduct, such as:
Market manipulation schemes involving false information spread through electronic and social media
Hacking to obtain material nonpublic information
Violations involving distributed ledger technology and initial coin offerings
Misconduct perpetrated using the dark web
Intrusions into retail brokerage accounts
Cyber-related threats to trading platforms and other critical market infrastructure
The unit, which has been in the planning stages for months, complements the Chairman’s initiatives to implement an internal cybersecurity risk profile and create a cybersecurity working group to coordinate information sharing, risk monitoring, and incident response efforts throughout the agency.
https://www.sec.gov/news/press-release/2017-176